Prexasertib

Drug Profile

Prexasertib

Alternative Names: Captisol® enabled prexasertib; LY 2606368; LY2606368 MsOH H2O

Latest Information Update: 01 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Array BioPharma; Eli Lilly
  • Developer Dana-Farber Cancer Institute; Eli Lilly; National Cancer Institute (USA)
  • Class Antineoplastics; Nitriles; Pyrazines; Pyrazoles; Small molecules
  • Mechanism of Action Checkpoint kinase 1 inhibitors; Checkpoint kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Solid tumours
  • Phase I Acute myeloid leukaemia; Colorectal cancer; Head and neck cancer; Myelodysplastic syndromes; Non-small cell lung cancer

Most Recent Events

  • 16 May 2018 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease) in USA (IV) (NCT03495323)
  • 12 Apr 2018 Eli Lilly in collaboration with Dana-Farber Cancer Institute plans I trial for Solid tumours (Late-stage disease) in USA (NCT03495323)
  • 09 Apr 2018 Phase-II clinical trials in Fallopian tube cancer (Second-line therapy or greater) in United Kingdom, Spain, South Korea, Italy, Israel, Belgium, Australia, USA (IV) (NCT03414047) (EudraCT2017-004009-42)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top